The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Donald E. Low

Mount Sinai Hospital/University Health Network





Name/email consistency: high



  • Mount Sinai Hospital/University Health Network, Toronto, Ontario, Canada. 2011
  • Department of Microbiology, Mount Sinai Hospital and University of Toronto, Canada. 2001 - 2009
  • Department of Microbiology, Toronto Medical Laboratories, Mount Sinai Hospital, Room 1487. 2002 - 2004
  • Mount Sinai Hospital, Department of Microbiology, University of Toronto, 600 University Avenue. 2004
  • Mount Sinai Hospital, Toronto, Canada. 2004


  1. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. Low, D.E., File, T.M., Eckburg, P.B., Talbot, G.H., David Friedland, H., Lee, J., Llorens, L., Critchley, I.A., Thye, D.A. J. Antimicrob. Chemother. (2011) [Pubmed]
  2. Antimicrobial susceptibility among bacterial isolates from ICU and non-ICU setting and different age groups: results from the tigecycline evaluation and Surveillance trial in North America. Low, D.E., Markovic, M.J., Dowzicky, M.J. J. Chemother (2009) [Pubmed]
  3. Reducing antibiotic use in influenza: challenges and rewards. Low, D. Clin. Microbiol. Infect. (2008) [Pubmed]
  4. Pandemic planning: non-pharmaceutical interventions. Low, D.E. Respirology (2008) [Pubmed]
  5. Progressive and nonresolving pneumonia. Low, D.E., Mazzulli, T., Marrie, T. Curr. Opin. Pulm. Med (2005) [Pubmed]
  6. Changing trends in antimicrobial-resistant pneumococci: it's not all bad news. Low, D.E. Clin. Infect. Dis. (2005) [Pubmed]
  7. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies. Low, D.E., Brown, S., Felmingham, D. Clin. Microbiol. Infect. (2004) [Pubmed]
  8. Why SARS will not return: a polemic. Low, D.E. CMAJ (2004) [Pubmed]
  9. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Low, D.E. Clin. Infect. Dis. (2004) [Pubmed]
  10. Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections. Low, D.E., Felmingham, D., Brown, S.D., Rangaraju, M., Nusrat, R. J. Infect. (2004) [Pubmed]
  11. Resistance trends in Haemophilus influenzae (PROTEKT years 1-3 [1999-20021). Low, D.E. J. Chemother (2004) [Pubmed]
  12. Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance. Low, D.E., Muller, M., Duncan, C.L., Willey, B.M., de Azavedo, J.C., McGeer, A., Kreiswirth, B.N., Pong-Porter, S., Bast, D.J. Antimicrob. Agents Chemother. (2002) [Pubmed]
  13. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Low, D.E., de Azavedo, J., Weiss, K., Mazzulli, T., Kuhn, M., Church, D., Forward, K., Zhanel, G., Simor, A., McGeer, A. Antimicrob. Agents Chemother. (2002) [Pubmed]
  14. Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus. Low, D.E., Kreiswirth, B.N., Weiss, K., Willey, B.M. Int. J. Antimicrob. Agents (2002) [Pubmed]
  15. The era of antimicrobial resistance-implications for the clinical laboratory. Low, D.E. Clin. Microbiol. Infect. (2002) [Pubmed]
  16. Antimicrobial drug use and resistance among respiratory pathogens in the community. Low, D.E. Clin. Infect. Dis. (2001) [Pubmed]
WikiGenes - Universities